Levodopa methyl ester treatment of Parkinson’s disease

J. L. Juncos, M Maral Mouradian, G. Fabbrini, C. Serrati, T. N. Chase

Research output: Contribution to journalArticle

41 Citations (Scopus)

Abstract

Intravenously administered levodopa is effective although relatively impractical for the chronic treatment of patients with Parkinson’s disease who are disabled by motor fluctuation. In view of its greater solubility, levodopa methyl ester (LDME) was evaluated in seven advanced parkinsonian patients as a potentially more convenient alternative. Compared with oral levodopa, LDME infusions resulted in marked reductions of both plasma levodopa variations and motor response fluctuations in patients with either wearing-off or on-off phenomena. During infusions lasting approximately 1 week, there were no complications except for peripheral vein phlebitis. The results suggest that LDME might be a practical parenteral treatment for those with severe Parkinson’s disease. It appears that central venous access or its equivalent will be necessary for its chronic administration.

Original languageEnglish (US)
Pages (from-to)1242-1245
Number of pages4
JournalNeurology
Volume37
Issue number7
StatePublished - Jan 1 1987
Externally publishedYes

Fingerprint

Levodopa
Parkinson Disease
Phlebitis
Solubility
Veins
Therapeutics
levodopa methyl ester

All Science Journal Classification (ASJC) codes

  • Clinical Neurology

Cite this

Juncos, J. L., Mouradian, M. M., Fabbrini, G., Serrati, C., & Chase, T. N. (1987). Levodopa methyl ester treatment of Parkinson’s disease. Neurology, 37(7), 1242-1245.
Juncos, J. L. ; Mouradian, M Maral ; Fabbrini, G. ; Serrati, C. ; Chase, T. N. / Levodopa methyl ester treatment of Parkinson’s disease. In: Neurology. 1987 ; Vol. 37, No. 7. pp. 1242-1245.
@article{cc271972084a4ac3a92c25f1af9db0dd,
title = "Levodopa methyl ester treatment of Parkinson’s disease",
abstract = "Intravenously administered levodopa is effective although relatively impractical for the chronic treatment of patients with Parkinson’s disease who are disabled by motor fluctuation. In view of its greater solubility, levodopa methyl ester (LDME) was evaluated in seven advanced parkinsonian patients as a potentially more convenient alternative. Compared with oral levodopa, LDME infusions resulted in marked reductions of both plasma levodopa variations and motor response fluctuations in patients with either wearing-off or on-off phenomena. During infusions lasting approximately 1 week, there were no complications except for peripheral vein phlebitis. The results suggest that LDME might be a practical parenteral treatment for those with severe Parkinson’s disease. It appears that central venous access or its equivalent will be necessary for its chronic administration.",
author = "Juncos, {J. L.} and Mouradian, {M Maral} and G. Fabbrini and C. Serrati and Chase, {T. N.}",
year = "1987",
month = "1",
day = "1",
language = "English (US)",
volume = "37",
pages = "1242--1245",
journal = "Neurology",
issn = "0028-3878",
publisher = "Lippincott Williams and Wilkins Ltd.",
number = "7",

}

Juncos, JL, Mouradian, MM, Fabbrini, G, Serrati, C & Chase, TN 1987, 'Levodopa methyl ester treatment of Parkinson’s disease', Neurology, vol. 37, no. 7, pp. 1242-1245.

Levodopa methyl ester treatment of Parkinson’s disease. / Juncos, J. L.; Mouradian, M Maral; Fabbrini, G.; Serrati, C.; Chase, T. N.

In: Neurology, Vol. 37, No. 7, 01.01.1987, p. 1242-1245.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Levodopa methyl ester treatment of Parkinson’s disease

AU - Juncos, J. L.

AU - Mouradian, M Maral

AU - Fabbrini, G.

AU - Serrati, C.

AU - Chase, T. N.

PY - 1987/1/1

Y1 - 1987/1/1

N2 - Intravenously administered levodopa is effective although relatively impractical for the chronic treatment of patients with Parkinson’s disease who are disabled by motor fluctuation. In view of its greater solubility, levodopa methyl ester (LDME) was evaluated in seven advanced parkinsonian patients as a potentially more convenient alternative. Compared with oral levodopa, LDME infusions resulted in marked reductions of both plasma levodopa variations and motor response fluctuations in patients with either wearing-off or on-off phenomena. During infusions lasting approximately 1 week, there were no complications except for peripheral vein phlebitis. The results suggest that LDME might be a practical parenteral treatment for those with severe Parkinson’s disease. It appears that central venous access or its equivalent will be necessary for its chronic administration.

AB - Intravenously administered levodopa is effective although relatively impractical for the chronic treatment of patients with Parkinson’s disease who are disabled by motor fluctuation. In view of its greater solubility, levodopa methyl ester (LDME) was evaluated in seven advanced parkinsonian patients as a potentially more convenient alternative. Compared with oral levodopa, LDME infusions resulted in marked reductions of both plasma levodopa variations and motor response fluctuations in patients with either wearing-off or on-off phenomena. During infusions lasting approximately 1 week, there were no complications except for peripheral vein phlebitis. The results suggest that LDME might be a practical parenteral treatment for those with severe Parkinson’s disease. It appears that central venous access or its equivalent will be necessary for its chronic administration.

UR - http://www.scopus.com/inward/record.url?scp=0023237437&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0023237437&partnerID=8YFLogxK

M3 - Article

VL - 37

SP - 1242

EP - 1245

JO - Neurology

JF - Neurology

SN - 0028-3878

IS - 7

ER -

Juncos JL, Mouradian MM, Fabbrini G, Serrati C, Chase TN. Levodopa methyl ester treatment of Parkinson’s disease. Neurology. 1987 Jan 1;37(7):1242-1245.